Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Valeant

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Valeant's Japan sales performance.

valeant

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands Looking to distance itself from toxic past, Valeant to rebrand as Bausch Health. ... Valeant’s years of buccaneering mergers and acquisitions, suspect business practices and allegations of fraud have left it saddled with debt and a pariah-like status

Sun Pharma passes milestone with novel psoriasis drug approval

Sun Pharma passes milestone with novel psoriasis drug approval IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).

AbbVie reports more solid data for would-be psoriasis blockbuster

AbbVie reports more solid data for would-be psoriasis blockbuster ixekizumab) and Valeant’s Siliq (brodalumab).

Lilly claims another EU okay for Taltz

Lilly claims another EU okay for Taltz leader. A third IL-17 drug - Valeant’s Siliq (brodalumab) - was launched in the third quarter in the US at a discount to Cosentyx and Taltz but the company has yet

Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown

Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown Cosentyx was the first IL-17 inhibitor to reach the market and has been growing quickly, despite facing competition from more recent IL-17 inhibitor entrants from Eli Lilly and Valeant,

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics